Drug Approval | August 11, 2025
Shilpa Medicare receives approval of NorUDCA tablets for treatment of NAFLD in India
NorUDCA is the first?in?class treatment for Non?alcoholic Fatty Liver Disease (NAFLD) in India
NorUDCA is the first?in?class treatment for Non?alcoholic Fatty Liver Disease (NAFLD) in India
The Q-Switched Nd:YAG system is suitable for all skin types and offers versatility in treating dermal and epidermal pigmentation
Vasograin Plus represents a major advancement in the treatment of migraine
Loteprednol Etabonate Ophthalmic Suspension, 0.5% is indicated for the treatment of steroidresponsive inflammatory conditions of the palpebral and bulbar conjunctiva
Celecoxib is a nonsteroidal anti-inflammatory drug
Finerenone significantly reduced the combined risk of cardiovascular death and total (first and recurrent) heart failure events,
Acquisition aligns with Merck’s science-led business development strategy and expands pipeline and portfolio of treatments for cardio-pulmonary diseases
his is the second license extension of a Nurix autoimmune disease program by Sanofi in the last 90 days
The trial targets MCAS/MCAD, an under-recognized, debilitating condition with an unknown cause and no cure
Usnoflast has previously also received ‘Orphan Drug Designation (ODD)’ from the USFDA
Subscribe To Our Newsletter & Stay Updated
